RLAY [NASD]
Relay Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own0.50% Shs Outstand108.64M Perf Week15.54%
Market Cap2.75B Forward P/E- EPS next Y-3.10 Insider Trans-28.05% Shs Float106.14M Perf Month27.58%
Income-267.10M PEG- EPS next Q-0.71 Inst Own- Short Float17.35% Perf Quarter56.29%
Sales2.00M P/S1373.08 EPS this Y-49.40% Inst Trans7.32% Short Ratio17.06 Perf Half Y12.67%
Book/sh7.18 P/B3.53 EPS next Y-13.50% ROA-30.40% Target Price39.00 Perf Year-25.07%
Cash/sh7.74 P/C3.28 EPS next 5Y- ROE-34.60% 52W Range12.65 - 38.15 Perf YTD-17.45%
Dividend- P/FCF- EPS past 5Y- ROI-40.60% 52W High-20.09% Beta-
Dividend %- Quick Ratio19.50 Sales past 5Y- Gross Margin- 52W Low140.99% ATR2.09
Employees305 Current Ratio19.50 Sales Q/Q-50.00% Oper. Margin- RSI (14)69.61 Volatility10.08% 9.64%
OptionableYes Debt/Eq0.00 EPS Q/Q66.40% Profit Margin- Rel Volume13.22 Prev Close25.35
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout- Avg Volume1.08M Price30.49
Recom2.10 SMA2036.16% SMA5046.67% SMA20029.77% Volume2,208,081 Change20.26%
Sep-02-22Initiated Stifel Buy $40
Jun-06-22Initiated Jefferies Underperform $13
Feb-01-22Initiated Berenberg Buy $45
Jul-21-21Initiated BofA Securities Buy $50
Dec-15-20Reiterated H.C. Wainwright Buy $54 → $57
Dec-08-20Initiated JMP Securities Mkt Outperform $66
Nov-05-20Initiated H.C. Wainwright Buy $54
Aug-10-20Initiated JP Morgan Neutral $36
Aug-10-20Initiated Guggenheim Buy $48
Aug-10-20Initiated Goldman Buy $64
Aug-10-20Initiated Cowen Outperform
Aug-30-22 11:15AM  
Aug-25-22 02:48PM  
Aug-18-22 04:05PM  
Aug-04-22 04:05PM  
Jul-28-22 04:05PM  
Jun-27-22 06:00AM  
Jun-16-22 07:30AM  
May-26-22 07:30AM  
May-07-22 09:59AM  
May-05-22 04:05PM  
May-03-22 07:30AM  
Apr-28-22 04:05PM  
Feb-24-22 04:05PM  
Feb-17-22 04:05PM  
Feb-10-22 11:51AM  
Feb-02-22 07:30AM  
Jan-04-22 07:30AM  
Jan-03-22 07:30AM  
Dec-22-21 11:11AM  
Dec-18-21 12:38AM  
Dec-10-21 07:30AM  
Nov-17-21 11:39AM  
Nov-16-21 12:36PM  
Nov-10-21 04:05PM  
Nov-04-21 04:05PM  
08:14AM  
Oct-27-21 01:23PM  
04:50AM  
Oct-15-21 09:01AM  
Oct-12-21 09:58PM  
04:27AM  
Oct-11-21 04:15PM  
Oct-08-21 12:24PM  
06:00AM  
Oct-07-21 08:50AM  
Sep-13-21 06:00AM  
Aug-18-21 10:27AM  
Aug-15-21 04:06AM  
Aug-12-21 04:05PM  
Aug-05-21 04:05PM  
Jul-20-21 10:48PM  
Jul-19-21 09:26AM  
Jun-02-21 06:00AM  
May-14-21 06:00AM  
May-13-21 04:05PM  
May-10-21 06:00AM  
May-05-21 06:00AM  
May-03-21 06:00AM  
Apr-16-21 11:31AM  
06:00AM  
Apr-14-21 05:57AM  
Mar-25-21 04:05PM  
Mar-10-21 04:30PM  
Feb-04-21 04:05PM  
Jan-14-21 04:26AM  
Jan-06-21 05:00PM  
06:00AM  
Dec-16-20 10:36PM  
Dec-14-20 06:00AM  
Nov-12-20 04:05PM  
Oct-16-20 10:53AM  
Sep-03-20 04:05PM  
Aug-27-20 06:50AM  
Aug-16-20 08:59AM  
Aug-11-20 06:40AM  
Aug-06-20 06:07PM  
Jul-20-20 04:05PM  
Jul-17-20 04:17PM  
Jul-16-20 04:28PM  
01:25PM  
12:02PM  
Jul-15-20 08:51PM  
07:34AM  
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bergstrom Donald APresident, R&DSep 02Option Exercise4.124,90020,18894,559Sep 02 05:47 PM
Bergstrom Donald APresident, R&DSep 02Sale25.464,900124,75489,659Sep 02 05:47 PM
Bergstrom Donald APresident, R&DSep 01Option Exercise4.128,10033,37297,759Sep 01 08:26 PM
Bergstrom Donald APresident, R&DSep 01Sale23.078,100186,86789,659Sep 01 08:26 PM
Bergstrom Donald APresident, R&DAug 24Option Exercise4.1215,00061,800104,659Aug 25 05:23 PM
Bergstrom Donald APresident, R&DAug 24Sale25.0015,000375,00089,659Aug 25 05:23 PM
Bergstrom Donald APresident, R&DAug 05Option Exercise4.128,00032,96097,659Aug 08 05:38 PM
Bergstrom Donald APresident, R&DAug 05Sale20.008,000160,00089,659Aug 08 05:38 PM
Porter AndyChief Administrative OfficerJul 28Sale21.274529,61445,871Jul 29 04:57 PM
Catinazzo ThomasChief Financial OfficerJul 28Sale21.2673415,60552,218Jul 29 04:53 PM
Bergstrom Donald APresident, R&DJul 28Sale21.271,83539,03089,659Jul 29 04:45 PM
Adams BrianChief Legal OfficerJul 28Sale21.2773415,61262,842Jul 29 04:42 PM
Bergstrom Donald APresident, R&DJul 06Option Exercise4.128,00032,96099,494Jul 08 04:17 PM
Bergstrom Donald APresident, R&DJul 06Sale20.008,000160,00091,494Jul 08 04:17 PM
Porter AndyChief Administrative OfficerJun 27Sale20.312655,38246,323Jun 28 06:03 PM
Catinazzo ThomasChief Financial OfficerJun 27Sale20.313006,09352,952Jun 28 05:59 PM
Adams BrianChief Legal OfficerJun 27Sale20.313006,09363,576Jun 28 05:56 PM
Bergstrom Donald APresident, R&DJun 27Sale20.3199920,29091,494Jun 28 05:53 PM
Bergstrom Donald APresident, R&DJun 24Option Exercise4.128,00032,960100,493Jun 28 05:53 PM
Bergstrom Donald APresident, R&DJun 24Sale20.008,000160,00092,493Jun 28 05:53 PM
Bergstrom Donald APresident, R&DMay 02Option Exercise4.1213,00053,560105,493May 02 08:24 PM
Bergstrom Donald APresident, R&DMay 02Sale24.6213,000320,06092,493May 02 08:24 PM
Bergstrom Donald APresident, R&DApr 28Sale25.571,81146,30792,493May 02 08:24 PM
Porter AndyChief Administrative OfficerApr 28Sale25.5743511,12346,588May 02 08:13 PM
Catinazzo ThomasChief Financial OfficerApr 28Sale25.5772518,53853,252May 02 08:07 PM
Adams BrianChief Legal OfficerApr 28Sale25.5770818,10463,876May 02 08:03 PM
Patel SanjivPresident and CEOApr 14Option Exercise4.5828,000128,240267,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 14Sale30.5128,000854,280253,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 13Option Exercise4.5828,000128,240267,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 13Sale31.9528,000894,600253,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 12Option Exercise4.1228,000115,360281,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 12Sale31.8028,000890,400253,740Apr 14 09:20 PM
Bergstrom Donald APresident, R&DApr 01Option Exercise4.1218,00074,160112,304Apr 05 05:32 PM
Bergstrom Donald APresident, R&DApr 01Sale30.3218,000545,76094,304Apr 05 05:32 PM
Porter AndyChief Administrative OfficerMar 29Sale29.872948,78247,023Mar 31 05:49 PM
Catinazzo ThomasChief Financial OfficerMar 29Sale29.872828,42353,977Mar 31 05:45 PM
Adams BrianChief Legal OfficerMar 29Sale29.873339,94764,584Mar 31 05:37 PM
Bergstrom Donald APresident, R&DMar 29Sale29.8762218,57994,304Mar 31 05:41 PM
Bergstrom Donald APresident, R&DMar 24Option Exercise4.1210,00041,200104,926Mar 28 08:11 PM
Catinazzo ThomasChief Financial OfficerMar 24Option Exercise4.1213,28654,73867,545Mar 28 08:18 PM
Catinazzo ThomasChief Financial OfficerMar 24Sale30.0013,286398,58054,259Mar 28 08:18 PM
Bergstrom Donald APresident, R&DMar 24Sale30.0010,000300,00094,926Mar 28 08:11 PM
Bergstrom Donald APresident, R&DMar 10Option Exercise4.1210,00041,200104,926Mar 11 07:02 PM
Bergstrom Donald APresident, R&DMar 10Sale25.0010,000250,00094,926Mar 11 07:02 PM
Bergstrom Donald APresident, R&DMar 01Option Exercise4.128,00032,960102,926Mar 03 05:31 PM
Bergstrom Donald APresident, R&DMar 01Sale23.888,000191,04094,926Mar 03 05:31 PM
Bergstrom Donald APresident, R&DFeb 22Option Exercise4.128,00032,960117,920Feb 22 09:01 PM
Bergstrom Donald APresident, R&DFeb 22Sale20.9422,994481,57794,926Feb 22 09:01 PM
Catinazzo ThomasSenior Vice President, FinanceDec 27Sale33.102959,76414,989Dec 27 07:43 PM
Porter AndySee RemarksDec 27Sale33.102608,60623,147Dec 27 07:50 PM
Bergstrom Donald ASee RemarksDec 27Sale33.1064921,48244,970Dec 27 07:39 PM
Adams BrianGeneral CounselDec 27Sale33.102959,76424,989Dec 27 07:31 PM
Catinazzo ThomasSenior Vice President, FinanceNov 15Option Exercise4.1222,50092,70037,784Nov 16 07:14 PM
Adams BrianGeneral CounselNov 15Option Exercise4.126,50026,78031,784Nov 16 07:07 PM
Adams BrianGeneral CounselNov 15Sale35.426,500230,23025,284Nov 16 07:07 PM
Catinazzo ThomasSenior Vice President, FinanceNov 15Sale35.4022,500796,50015,284Nov 16 07:14 PM
Bergstrom Donald ASee RemarksOct 15Sale34.1530,0001,024,50045,619Oct 19 08:56 PM
Catinazzo ThomasSenior Vice President, FinanceSep 27Sale36.8729310,80315,284Sep 27 09:33 PM
Bergstrom Donald ASee RemarksSep 27Sale36.8764623,81875,619Sep 27 09:27 PM
Adams BrianGeneral CounselSep 27Sale36.8729310,80325,284Sep 27 09:21 PM
Catinazzo ThomasSenior Vice President, FinanceSep 13Option Exercise4.1222,50092,70038,077Sep 13 08:24 PM
Adams BrianGeneral CounselSep 13Option Exercise4.126,50026,78032,077Sep 13 08:27 PM
Catinazzo ThomasSenior Vice President, FinanceSep 13Sale35.0022,500787,50015,577Sep 13 08:24 PM
Adams BrianGeneral CounselSep 13Sale35.026,500227,63025,577Sep 13 08:27 PM